Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Anlotinib and Chemotherapy in Retroperitoneal Sarcoma
NCT05844813Phase 4Enrolling by invitation
- Sponsor
- Peking University International Hospital
- Start
- Nov 2022
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of anlotinib in retroperitoneal sarcoma (RPS), sponsored by Peking University International Hospital. Started Nov 2022; status: enrolling by invitation.
02
Drugs
anlotinib
03
Conditions
retroperitoneal sarcoma (RPS)
Beyond the preview
Go deeper on NCT05844813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05844813.